Hip pain is becoming one the most common issues for adults as we age. Treatment options are few and degeneration can be caused by many factors, well noted in the medical literature. Our purpose is to help educate suffers of hip pain about regenerative medicine options like platelet rich plasma, (PRP), adult stem cells treatment. These adult stem cell therapies are obtained using the patients own blood, adipose ( fat ) or juvenile mesenchymal stem cells. In some late stage cases only surgery is an option, but these treatments can also be combined to help healing.
Above is a hip replacement surgery. Many patients have avoided this type of procedure and have used adult stem cells or platelet rich plasma non surgical injections to support regeneration of the joint, reducing pain.How does Platelet Rich Plasma work ?
The procedure involves a standard blood draw from the patient. It is painless and takes about 10 minutes. The trained and certified technician will use a sterile procedure to process the blood obtaining millions of platelet and may add adult stem cells. These will be activated using a special Laser Light source to increase the activities of the cells in your blood. This “activation ” of your cells is critical, if not activated the cells are dormant and will not signal damaged tissue to heal. The solution of cells is then injected into your hip joint or joints by the doctor under local anesthesia, again a painless process. Your cells will adhere to damaged hip tissue and signal the regeneration process to start.
Below is published peer reviewed research on using adult stem cells to treat hip pain.
Matthew T Houdek
Cody C Wyles
John R Martin
Rafael J Sierra, Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN
Avascular necrosis (AVN) of the femoral head is a progressive disease that pre-dominantly affects younger patients. Although the exact pathophysiology of AVN has yet to be elucidated, the disease is characterized by a vascular insult to the blood supply of the femoral head, which can lead to collapse of the femoral head and subsequent degenerative changes. If AVN is diagnosed in the early stages of the disease, it may be possible to attempt surgical pro-cedures which preserve the hip joint, including decompression of the femoral head augmented with concentrated bone marrow. The use of autologous stem cells has shown promise in halting the progression of AVN of the femoral head, and subsequently preventing young patients from undergoing total hip arthroplasty. The purpose of this study was to review the current use of stem cells for the treatment of AVN of the femoral head.
Arch Iran Med. 2015 Jun;18(6):336-44. doi: 015186/AIM.003.
Emadedin M1, Ghorbani Liastani M2, Fazeli R3, Mohseni F3, Moghadasali R3, Mardpour S3, Hosseini SE3, Niknejadi M3, Moeininia F3, Aghahossein Fanni A3, Baghban Eslaminejhad R3, Vosough Dizaji A4, Labibzadeh N3, Mirazimi Bafghi A3, Baharvand H3, Aghdami N5.
Osteoarthritis (OA) is a debilitating disease that typically affects a large number of the middle-aged and elderly population. Current treatment strategies have had limited success in these patients. This study aims to investigate the safety of treatment with autologous bone marrow (BM)-derived mesenchymal stem cells (MSCs) transplanted in patients with OA of the knee, ankle, or hip.
We enrolled 18 patients with different joint involvements (knee, ankle, or hip OA) and one was lost to follow-up. BM samples were taken from the patients, after which BM-derived MSCs were isolated and cultured. Each patient received one MSC injection. Patients were followed with clinical examinations, MRI and laboratory tests at 2, 6, 12, and 30 months post-transplantation.
We observed no severe adverse events such as pulmonary embolism, death, or systemic complications. A limited number of patients had very minor localized adverse effects such as rash and erythema. There were no changes in liver function, hematology, or biochemistry analyses before and after cell therapy. There was no evidence of tumor or neoplastic changes in the patients during the 30-month follow-up period. All patients exhibited therapeutic benefits such as increased walking distance, decreased visual analog scale (VAS), and total Western Ontario and McMaster Universities OA Index (WOMAC) scores which were confirmed by MRI.
Our study has shown that injection of MSCs in different OA affected joints is safe and therapeutically beneficial. However, further studies are needed with larger sample sizes and longer follow-up periods to confirm these findings.
ClinicalTrials.gov NCT01207661 NCT01436058 NCT01499056.
Transplant Proc. 2014 Jan-Feb;46(1):151-5. doi: 10.1016/j.transproceed.2013.06.021.
Cai J1, Wu Z1, Huang L1, Chen J1, Wu C1, Wang S1, Deng Z1, Wu W1, Luo F1, Tan J2.
We sought to investigate the therapeutic effects of cotransplantation of autologous bone marrow mononuclear cells (BMMNCs) and allogeneic umbilical cord mesenchymal stem cells (UC-MSCs) on avascular necrosis of the femoral head (ANFH).
In all, 30 patients (49 hips; 24 males and 6 females) with ANFH were enrolled. According to the system of the Association Research Circulation Osseous, there were 24 hips in phase II and 25 hips in phase Ⅲ. Blood supply to the femoral head was evaluated by using digital subtraction angiography. Generally, 60 to 80 mL of autologous BMMNCs and 30 to 50 mL of UC-MSCs were infused into the femoral head artery. Harris scores including pain and joint function were used to evaluate the effects before and 3, 6, 9, and 12 months after transplantation. Computed tomography and radiographs were performed before and 12 months after the treatment.
Clinical symptoms of pain and claudication were gradually improved. After the treatment, 93.3% (28/30), 86.7% (26/30), and 86.7% (26/30) of patients showed relief of hip pain, improvement of joint function, and extended walking distances, respectively. The Harris scores were increased significantly at 3, 6, and 12 months posttransplant compared with those pretransplant. In addition, the bone lesions in 89.7% of hips (44/49) were improved as showed on computed tomography after transplantation.
Cotransplantation of autologous BMMNCs and allogeneic UC-MSCs showed therapeutic effect on ANFH without severe adverse effects.
Copyright © 2014 Elsevier Inc. All rights reserved.